Schuster DM - Search Results

1

Savir-Baruch B, Werner RA, Rowe SP, Schuster DM. Savir-Baruch B, et al. Among authors: schuster dm. Radiol Clin North Am. 2021 Sep;59(5):801-811. doi: 10.1016/j.rcl.2021.05.008. Radiol Clin North Am. 2021. PMID: 34392920 Review.

2

Molecular imaging in breast cancer.

Schuster DM, Halkar RK. Schuster DM, et al. Radiol Clin North Am. 2004 Sep;42(5):885-908, vi-vii. doi: 10.1016/j.rcl.2004.06.001. Radiol Clin North Am. 2004. PMID: 15337423 Review.

3

F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer.

Koshy M, Paulino AC, Howell R, Schuster D, Halkar R, Davis LW. Koshy M, et al. Head Neck. 2005 Jun;27(6):494-502. doi: 10.1002/hed.20179. Head Neck. 2005. PMID: 15772951

4

Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer.

Paulino AC, Koshy M, Howell R, Schuster D, Davis LW. Paulino AC, et al. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1385-92. doi: 10.1016/j.ijrobp.2004.08.037. Int J Radiat Oncol Biol Phys. 2005. PMID: 15817341

5

PET-CT vs contrast-enhanced CT: what is the role for each after chemoradiation for advanced oropharyngeal cancer?

Chen AY, Vilaseca I, Hudgins PA, Schuster D, Halkar R. Chen AY, et al. Head Neck. 2006 Jun;28(6):487-95. doi: 10.1002/hed.20362. Head Neck. 2006. PMID: 16619274

6

Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.

Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, Bowman FD, Issa MM, Goodman MM. Schuster DM, et al. J Nucl Med. 2007 Jan;48(1):56-63. J Nucl Med. 2007. PMID: 17204699 Free article.

7

Case study of anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) to guide prostate cancer radiotherapy target design.

Jani AB, Fox TH, Whitaker D, Schuster DM. Jani AB, et al. Among authors: schuster dm. Clin Nucl Med. 2009 May;34(5):279-84. doi: 10.1097/RLU.0b013e31819e51e3. Clin Nucl Med. 2009. PMID: 19387202

8

Initial experience with the radiotracer anti-1-amino-3-[18F]Fluorocyclobutane-1-carboxylic acid (anti-[ 18F]FACBC) with PET in renal carcinoma.

Schuster DM, Nye JA, Nieh PT, Votaw JR, Halkar RK, Issa MM, Yu W, Sepulveda J, Zeng W, Young A, Goodman MM. Schuster DM, et al. Mol Imaging Biol. 2009 Nov-Dec;11(6):434-8. doi: 10.1007/s11307-009-0220-5. Epub 2009 May 16. Mol Imaging Biol. 2009. PMID: 19449079

9

Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in recurrent prostate carcinoma.

Savir-Baruch B, Schuster DM, Jarkas N, Master VA, Nieh PT, Halkar RK, Nye JA, Lewis MM, Crowe RJ, Voll RJ, Camp VM, Bellamy LM, Roberts DL, Goodman MM. Savir-Baruch B, et al. Among authors: schuster dm. Mol Imaging Biol. 2011 Dec;13(6):1272-7. doi: 10.1007/s11307-010-0445-3. Mol Imaging Biol. 2011. PMID: 20976627 Free PMC article.

10

Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.

Schuster DM, Savir-Baruch B, Nieh PT, Master VA, Halkar RK, Rossi PJ, Lewis MM, Nye JA, Yu W, Bowman FD, Goodman MM. Schuster DM, et al. Radiology. 2011 Jun;259(3):852-61. doi: 10.1148/radiol.11102023. Epub 2011 Apr 14. Radiology. 2011. PMID: 21493787 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

195 results

Search Page